Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this year. The company now expects full-year revenue to come in at roughly $1.26 ...

Tempus AI (TEM) has posted an impressive price move of 21% over the last week, likely influenced by a blend of recent developments. The company announced significant revenue growth in its second ...

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects. Click here to read why TEM is a Hold.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company’s adjusted loss of 24 cents was narrower than the Zacks Consensus ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...